| Not Yet Recruiting | Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer NCT07406594 | University of Vermont Medical Center | N/A |
| Not Yet Recruiting | Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer NCT07506876 | Legacy Health System | Phase 2 |
| Recruiting | A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer NCT07299825 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 2 |
| Active Not Recruiting | A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After NCT06100874 | Adrienne G. Waks | Phase 2 |
| Unknown | A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoa NCT05871918 | Tianjin Medical University Cancer Institute and Hospital | Phase 3 |
| Unknown | PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-posit NCT04644406 | Hospices Civils de Lyon | — |
| Active Not Recruiting | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer NCT02947685 | Alliance Foundation Trials, LLC. | Phase 3 |
| Completed | A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer NCT02675231 | Eli Lilly and Company | Phase 2 |
| Terminated | Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer NCT02598310 | Osaka Medical College | Phase 2 |
| Completed | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Ca NCT02492711 | MacroGenics | Phase 3 |
| Active Not Recruiting | T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA NCT02326974 | Dana-Farber Cancer Institute | Phase 2 |
| Completed | A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positiv NCT02488564 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Active Not Recruiting | Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer NCT02568839 | Thomas Hatschek | Phase 2 / Phase 3 |
| Completed | Strain Imaging in Breast Cancer Patients Receiving Trastuzumab NCT02080390 | University of Florida | — |
| Completed | Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer NCT02066532 | Dawn L. Hershman | Phase 1 / Phase 2 |
| Terminated | Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer NCT02154529 | Kadmon Corporation, LLC | Phase 1 / Phase 2 |
| Withdrawn | Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer NCT02102438 | Instituto do Cancer do Estado de São Paulo | N/A |
| Completed | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast NCT01583426 | GBG Forschungs GmbH | Phase 3 |
| Completed | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cance NCT01677455 | Synta Pharmaceuticals Corp. | Phase 2 |
| Completed | HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1 NCT01565200 | Jules Bordet Institute | Phase 2 |
| Completed | Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab NCT01432223 | Osaka Medical College | Phase 2 |
| Completed | A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases NCT01305941 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Terminated | Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer NCT01388647 | Vector Oncology | Phase 1 / Phase 2 |
| Completed | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer NCT01426880 | GBG Forschungs GmbH | Phase 2 / Phase 3 |
| Unknown | Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer NCT01428414 | Zhimin Shao | Phase 2 |
| Withdrawn | AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer NCT01361945 | Texas Tech University Health Sciences Center, El Paso | Phase 1 / Phase 2 |
| Completed | Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzuma NCT01340430 | Lucia Del Mastro,MD | Phase 2 |
| Terminated | A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Canc NCT02131506 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 1 |
| Completed | Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Comple NCT01433926 | Asociación para el Progreso de la Oncología en Málaga | — |
| Completed | A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With H NCT00788931 | Novartis Pharmaceuticals | Phase 1 |